COMPANY INFO
Enlaza Therapeutics, founded in 2020, is a biotechnology research company headquartered in San Diego, California. The company was co-founded by Dr. Sergio Duron and Dr. Sanford (Sandy) Madigan and employs between 51-200 people. Enlaza Therapeutics pioneers the development of first-in-class covalent protein therapeutics using their proprietary War-Lock technology to create highly selective biologic drugs that irreversibly bind to disease targets, aiming to transform the treatment of cancer and other serious diseases. Their approach enhances efficacy and safety by enabling sustained target occupancy with minimal systemic exposure. The company's website is https://enlazatx.com.
Enlaza Therapeutics, founded in 2020, is a biotechnology research company headquartered in San Diego, California. The company pioneers first-in-class covalent protein therapeutics using its proprietary War-Lock technology to develop highly selective biologic drugs for cancer and other serious diseases.
Enlaza Therapeutics’ leadership team blends decades of expertise across drug discovery, business operations, protein engineering, and translational research. The company’s founders and executives have a track record of building successful biotech ventures, guiding therapeutics through clinical development, and driving innovation at the intersection of molecular biology and business growth. Together, they form a robust management team poised to elevate Enlaza's mission and accelerate its impact on patient outcomes.
As Sergio Duron, Ph.D., Co-Founder and CEO, Dr. Duron leads Enlaza Therapeutics’ overall vision, strategy, and scientific innovation. He has spearheaded the company’s journey into covalent biologics, directing research efforts and expanding the proprietary War-Lock platform, which positions Enlaza to transform cancer and serious disease treatment. His leadership has been pivotal in building high-performing teams and forging productive partnerships to advance Enlaza's mission.
Dr. Duron holds a Ph.D. in Organic Chemistry from the University of Illinois at Urbana-Champaign and completed post-doctoral training at The Scripps Research Institute. Before founding Enlaza, he played major roles in Calporta Therapeutics, Sitari Pharmaceuticals, Afraxis, and Zacharon Pharmaceuticals, and currently serves as Managing Partner at Avalon BioVentures and CSO at Nerio Therapeutics.
Sanford (Sandy) Madigan, Ph.D. is the Co-Founder, President, and Chief Business Officer of Enlaza Therapeutics. He brings over 25 years of expertise in corporate financing, operations, business development, and M&A to the executive team. Dr. Madigan is instrumental in shaping Enlaza's business strategy, driving growth, and executing key partnerships. His influence spans mergers, IPOs, and successful exits across the biotech sector.
Dr. Madigan earned a Ph.D. in Genetics and a B.S. in Biochemistry from The State University of New York at Stony Brook, and completed post-doctoral training at The Salk Institute for Biological Studies. Prior to Enlaza, he held executive roles at Calporta Therapeutics, Ankasa Regenerative Therapeutics, and Nerio Therapeutics, and is a Managing Partner at Avalon BioVentures.
Analeah Heidt, Ph.D. serves as Chief Scientific Officer at Enlaza Therapeutics, overseeing scientific research and development. With 15 years of experience in biologic therapeutics, she has led teams delivering first-in-human IND applications and clinical biomarker strategies, catalyzing Enlaza's progress in oncology and immuno-oncology.
Dr. Heidt received her Ph.D. in Biochemistry and Molecular Biology from UCSF and completed post-doctoral training at the Genomics Institute of the Novartis Research Foundation. Her prior leadership at Novartis and Inhibrx provides deep expertise in translational sciences and drug development.
Sateesh Natarajan, Ph.D. leads CMC Product Development at Enlaza Therapeutics. With more than 20 years in protein therapeutics and biologic manufacturing, Dr. Natarajan has developed and overseen antibody-drug conjugate and biosimilar pipelines, and ensured process robustness and regulatory compliance in the company’s manufacturing efforts.
He holds a Ph.D. in Chemical and Biochemical Engineering (University of Maryland) and conducted post-doctoral research at Johns Hopkins Medical School. Dr. Natarajan's prior roles span Silverback Therapeutics, Dr. Reddy’s Laboratories, Dendreon, and Trubion.
Mark Baer oversees business development at Enlaza Therapeutics. With over two decades of experience in therapeutic antibody R&D, he is responsible for driving the company’s partnerships and strategic growth efforts, supporting key alliances that enhance the reach of Enlaza’s therapeutics.
Mark holds a Ph.D. in Biochemistry from UNC Chapel Hill and a B.A. in Biochemistry from Cornell University. His previous leadership roles at EnGen Bio and KaloBios Pharmaceuticals reflect his background in building high-performing discovery and development teams across the biotech sector.
Sanford Madigan leads corporate strategy and business operations at Enlaza Therapeutics, building on extensive leadership and business development success across the biotech industry. His work ensures alignment between Enlaza’s strategic priorities and operational execution, further advancing the company’s commercialization goals.
With a Ph.D. in Genetics and a B.S. in Biochemistry from SUNY Stony Brook, Sanford Madigan has steered several ventures to successful exits and played a pivotal role in multiple funding, growth, and integration initiatives.
S. L. is responsible for human resources at Enlaza Therapeutics, focusing on talent acquisition, organizational development, and employee engagement. Their work supports the company’s dynamic culture and ensures that hiring and retention strategies align with Enlaza’s mission and growth objectives.
An experienced HR executive, S. L. excels in managing HR operations and has a background in strategic workforce planning, contributing to a productive and innovative work environment.
E. R. manages Enlaza’s pharmacology and translational research programs, directly contributing to the progress of Enlaza’s therapeutic pipeline. Their role is crucial in bridging preclinical discoveries with clinical development initiatives.
E. R. combines expertise in protein sciences and translational medicine, with a proven history of advancing biologics research and fostering cross-functional collaboration among scientific teams.
J. R. heads chemistry research and development, supporting the design and development of novel molecules for Enlaza's drug pipeline. Their leadership ensures robust execution of drug discovery programs that reinforce the company’s innovative edge.
With a strong foundation in organic chemistry and medicinal chemistry, J. R. has contributed to multiple successful drug discovery projects and brings significant experience in drug design to the Enlaza management team.
C. S. manages HR operations and policy development to harmonize Enlaza's internal culture with its business objectives. Their responsibilities include employee relations, benefits administration, and sustaining workplace excellence.
With experience in HR leadership, C. S. supports organizational growth by promoting a cohesive, engaged, and high-performing team across the company.
The Enlaza Therapeutics leadership team is comprised of accomplished scientists, biotech entrepreneurs, and business strategists who share a commitment to innovation and patient impact. The company’s management structure fosters collaboration across research, development, and corporate functions—resulting in a dynamic environment that drives scientific discovery, operational efficiency, and commercial excellence. This cohesive executive group lays the foundation for Enlaza’s continued success in advancing breakthrough biologic therapeutics.
Websets is a powerful natural language search and data enrichment tool that helps you research executive teams for any company. Whether you're analyzing the Enlaza Therapeutics leadership team or exploring management structures at other organizations, Websets provides comprehensive insights into executive backgrounds, roles, and team dynamics.
With Websets, you can access detailed executive team profiles, management structures, and leadership insights through intuitive natural language queries. Sign up now to enhance your executive team research capabilities.